EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents

Endale Mulugeta iD, Tirusew Tegafaw iD, Ying Liu iD, Dejun Zhao iD, Xiaoran Chen, Ahrum Baek iD, Jihyun Kim iD, Yongmin Chang, Gang Ho Lee iD

Nanomaterials · 01.09.2025 · 15 (17) · 1340

DOI: 10.3390/nano15171340 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nanomaterials, online erschienen am 01.09.2025. Verfasst von Endale Mulugeta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Natural Sciences, Kyungpook National University, Taegu 41566, Republic of Korea. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program of the National Research Foundation (NRF), Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although numerous studies have investigated gadolinium oxide (Gd2O3) nanoparticles (NPs) as positive (T1) magnetic resonance imaging (MRI) contrast agents (CAs), comprehensive reviews on this topic remain scarce. Therefore, it is essential to evaluate their current status and outline prospects. Despite promising physicochemical properties such as considerably higher relaxivities compared to 3–5 s−1mM−1 of clinically approved Gd(III)-chelate contrast agents and encouraging results from in vivo animal studies such as highly improved contrast enhancements, drug loading, and tumor targeting, extensive in vivo toxicity assessments including long-term toxicity and formulation advancements suitable for renal excretion (d < ~3 nm) are still required for clinical translation. This review summarizes the synthesis, characterization, in vitro and in vivo toxicity, and in vivo MRI applications of surface-modified Gd2O3 NPs as T1 MRI CAs. Finally, future perspectives on the development of surface-modified Gd2O3 NPs as potential next-generation T1 MRI CAs are discussed.

Schlagwörter

Stichwörter der Autor:innen

MRIcontrast agentfuture aspectsgadolinium oxide nanoparticlesurface modification

Autor:innen und Institutionen

  • Department of Chemistry, College of Natural Sciences, Kyungpook National University, Taegu 41566, Republic of Korea.
  • Institute of Biomedical Engineering Research, Kyungpook National University, Taegu 41944, Republic of Korea.
  • Department of Chemistry Education, Teachers' College, Kyungpook National University, Taegu 41566, Republic of Korea.
  • Department of Molecular Medicine, School of Medicine, Kyungpook National University, Taegu 41944, Republic of Korea.

ORCID-Profile: Endale Mulugeta, Tirusew Tegafaw, Ying Liu, Dejun Zhao, Ahrum Baek, Jihyun Kim, Gang Ho Lee

Förderung

  • National Research Foundation of Korea
  • Basic Science Research Program of the National Research Foundation (NRF)
  • Ministry of Education

Zitieren

APA

Mulugeta, E., Tegafaw, T., Liu, Y., Zhao, D., Chen, X., Baek, A., Kim, J., Chang, Y., & Lee, G. H. (2025). Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents. Nanomaterials, 15(17), 1340. https://doi.org/10.3390/nano15171340

Vancouver

Mulugeta E, Tegafaw T, Liu Y, Zhao D, Chen X, Baek A, et al. Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents. Nanomaterials. 2025;15(17):1340. doi:10.3390/nano15171340

BibTeX
@article{Mulugeta2025,
  author = {Mulugeta, Endale and Tegafaw, Tirusew and Liu, Ying and Zhao, Dejun and Chen, Xiaoran and Baek, Ahrum and Kim, Jihyun and Chang, Yongmin and Lee, Gang Ho},
  title = {Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents},
  journal = {Nanomaterials},
  year = {2025},
  volume = {15},
  number = {17},
  pages = {1340},
  doi = {10.3390/nano15171340}
}
Kostenlos starten →